Advate is a lab-made version of clotting factor VIII, a protein that people with hemophilia A are missing or don’t produce enough of. It’s given as an intravenous infusion to control bleeding, prevent bleeding episodes, and manage bleeding during surgery. The FDA has approved it for both adults and children, including newborns.
How Advate Works
In a healthy person, factor VIII is one of several proteins that work together to form blood clots when a vessel is injured. People with hemophilia A produce little or no factor VIII, which means even minor injuries can cause prolonged or uncontrolled bleeding, particularly into joints and muscles.
Advate is a recombinant product, meaning it’s manufactured in a laboratory using genetically engineered cells rather than extracted from donated human blood. When infused into a vein, it temporarily replaces the missing factor VIII, allowing the blood to clot normally. The effect doesn’t last indefinitely, so repeated infusions are needed depending on the situation.
What It’s Used For
Advate has three main uses. The first is on-demand treatment, where it’s given after a bleed has already started. The second is routine prophylaxis, where regular infusions are scheduled every other day (three to four times per week) to prevent bleeds from happening in the first place. The third is perioperative management, meaning it’s used before, during, and after surgery to keep bleeding under control.
For patients on a prophylaxis schedule, clinical data show a median annual bleeding rate of about 2.0 breakthrough bleeds per year. In one study, 22 out of the patients on prophylaxis had zero bleeds throughout the entire study period.
How It’s Given
Advate comes as a powder that needs to be mixed with a liquid (called a diluent) before injection. Each package includes a reconstitution device called BAXJECT II, which connects the diluent vial to the powder vial and uses vacuum pressure to draw the liquid in. If your prescribed dose requires more than one vial, each vial is mixed separately with its own device.
Once prepared, the solution is drawn into a syringe and injected slowly into a vein over up to five minutes, at a maximum rate of 10 mL per minute. Many people with hemophilia A learn to infuse at home, either doing it themselves or with help from a caregiver. Children under six typically need more frequent dosing because their bodies process the factor VIII faster.
Storage
Advate is stored in the refrigerator, but it can be kept at room temperature (up to 25°C or 77°F) for as long as 168 days, which is about six months. Once it’s been stored at room temperature, it should not be returned to the fridge. This flexibility makes it easier to travel with or store in situations where refrigeration isn’t always available.
Common Side Effects
In clinical trials involving 418 patients, the most frequently reported side effects were relatively mild. Fever was the most common, occurring in 16% of patients. Headache and cough each occurred in 13%, and cold-like symptoms (nasopharyngitis) in 12%. Joint pain affected 8%, while vomiting, upper respiratory infections, nasal congestion, and diarrhea were each reported in 5% to 7% of patients.
These side effects are generally manageable and not specific to the infusion itself. Many of them, like coughs and ear infections, reflect the fact that a large portion of study participants were children.
Inhibitor Development
The most significant risk with any factor VIII replacement therapy is the development of inhibitors. These are antibodies the immune system creates against the infused factor VIII, essentially treating it as a foreign invader. When this happens, the medication becomes less effective or stops working entirely.
This risk is highest in previously untreated patients, particularly young children receiving factor VIII for the first time. A large European and Canadian study tracking nearly 1,400 previously untreated patients with severe hemophilia A found that inhibitors developed in about 26% of those treated with Advate. This rate is consistent with other standard recombinant factor VIII products: Kogenate/Helixate showed a rate of 30%, and plasma-derived factor VIII products had a somewhat lower rate of 20%. Patients who develop inhibitors need alternative treatment strategies, and their care becomes considerably more complex.
For people who have already been treated with factor VIII products without developing inhibitors, the risk of new inhibitor formation is much lower, though it’s still monitored through regular blood tests.